NEJM· @NEJM · X·· 2026-10-18精选AI 评分82
AI 导读
NEJM报道,III期随机试验HAELO中,体内基因编辑疗法lonvo-z使遗传性血管性水肿患者的发作率显著低于安慰剂组。完整试验结果与研究摘要已发布,链接为https://nej.md/4gaSsbi。
推荐理由
III期HAELO试验显示lonvo-z可显著降低遗传性血管性水肿发作率,为体内基因编辑的临床验证提供数据。
正文
In a phase 3, randomized trial of lonvo-z, an in vivo gene-editing therapy, patients with hereditary angioedema who received the drug had a significantly lower attack rate than those who received placebo. Full HAELO trial results and Research Summary: https://nej.md/4gaSsbi
来源:NEJM · x.com